TY - JOUR T1 - Functional respiratory imaging assessment of the aerosol deposition of inhaled levofloxacin in cystic fibrosis lungs JF - European Respiratory Journal JO - Eur Respir J DO - 10.1183/13993003.congress-2021.PA2192 VL - 58 IS - suppl 65 SP - PA2192 AU - Carsten Schwarz AU - Claudio Procaccianti AU - Dennis Belmans AU - Benjamin Mignot AU - Nicolas Schwenck AU - Xabier Murgia AU - Federico Bianco AU - Claudio Procaccianti Y1 - 2021/09/05 UR - http://erj.ersjournals.com/content/58/suppl_65/PA2192.abstract N2 - Background: Functional Respiratory Imaging (FRI) uses CT scans to render 3D models of the airway tree to predict aerosol lung deposition through computational fluid dynamics simulations. Quinsair® is an inhaled formulation of levofloxacin approved in adult cystic fibrosis (CF) patients with chronic Pseudomonas aeruginosa infection. The study aimed to investigate lung deposition when delivered via its approved device Zirela®.Methods: Aerosol characterization was performed according to the US Pharmacopeia. Mass median aerodynamic diameter was 3.56±0.15µm with a geometric standard deviation 1.51±0.04. The aerosol parameters were coupled with the 3D models derived by the CT scans of CF patients with mild (FEV1 >70 percent predicted (pp), n=7) and moderate (FEV1 40-70 pp, n=13) disease; breathing patterns averaged from historical CF patients’ records were used to refine the simulation.Results: Intrathoracic levofloxacin deposition rates were 39.5±13.0% and 37.0±13.6% of the delivered dose (DD) for mild and moderate CF patients, respectively. Deposition was divided into central and peripheral; although the latter was slightly higher in the mild CF group, there were no significant differences between groups (table). Interestingly, a significant correlation was found between the central-to-peripheral deposition (C/P) ratio and the FEV1pp (p=0.039).Conclusion: This FRI study predicts good deposition in patients with mild and moderate CF, and an interesting correlation between FEV1pp and C/P ratio. Minute volume (L)Rate (bpm)Central deposition (% of DD; mean±SD)Peripheral deposition (% of DD; mean±SD)Mild CF0.6082321.9±7.717.6±6Moderate CF0.7592122.6±10.314.41±6.4FootnotesCite this article as: European Respiratory Journal 2021; 58: Suppl. 65, PA2192.This abstract was presented at the 2021 ERS International Congress, in session “Prediction of exacerbations in patients with COPD”.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only). ER -